Current Assets
Accounts Receivable
Pfizer Accounts Receivable increased by 6.0% to $12.59B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.2%, from $11.85B to $12.59B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 8.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase relative to sales may signal collection issues, while a decrease suggests efficient cash conversion cycles.
Detailed definition
This represents the balance of money owed to the company by customers for goods or services delivered, adjusted for an a...
Peer comparison
Standard across all industries; pharmaceutical companies often have longer cycles due to complex payer systems.
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.59B | $11.9B | $11.48B | $13.23B | $15.16B | $16.08B | $10.95B | $12.31B | $10.23B | $11.09B | $11.57B | $10.99B | $11.39B | $14.45B | $11.46B | $11.85B | $12.08B | $14.26B | $11.87B | $12.59B |
| QoQ Change | — | +12.4% | -3.5% | +15.2% | +14.6% | +6.1% | -31.9% | +12.4% | -16.9% | +8.4% | +4.3% | -5.0% | +3.7% | +26.8% | -20.7% | +3.3% | +2.0% | +18.1% | -16.7% | +6.0% |
| YoY Change | — | — | — | — | +43.1% | +35.1% | -4.6% | -7.0% | -32.5% | -31.0% | +5.6% | -10.7% | +11.4% | +30.4% | -0.9% | +7.8% | +6.0% | -1.3% | +3.6% | +6.2% |
Range$10.23B – $16.08B
CAGR+3.7%
Avg YoY Growth+3.8%
Median YoY Growth+4.6%
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Pfizer's accounts receivable?
- Pfizer (PFE) reported accounts receivable of $12.59B in Q1 2026.
- How has Pfizer's accounts receivable changed year-over-year?
- Pfizer's accounts receivable increased by 6.2% year-over-year, from $11.85B to $12.59B.
- What is the long-term trend for Pfizer's accounts receivable?
- Over 5 years (2020 to 2025), Pfizer's accounts receivable has grown at a 8.5% compound annual growth rate (CAGR), from $7.91B to $11.87B.
- What does accounts receivable mean?
- The amount of money customers owe the company for products already delivered.